NLS Pharmaceutics CEO Issues Letter To Shareholders
NLS Pharmaceutics CEO Issues Letter To Shareholders
NLS Pharmacetics 首席执行官致函股东
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announces that its Chief Executive Officer, Alex Zwyer, has issued the following letter to shareholders:
致力于发现和开发治疗罕见和复杂中枢神经系统疾病患者的创新疗法的瑞士临床期生物制药公司NLS制药有限公司(纳斯达克代码：NLSP)(纳斯达克代码：NLSPW)(以下简称“NLS”或“公司”)今天宣布，其首席执行官亚历克斯·兹怀尔已致信股东如下：
To our Shareholders and Friends,
致我们的股东和朋友：
Just under two years ago, NLS Pharmaceutics sought your investment and support to advance our pipeline in rare sleep disorders and other rare and debilitating Central Nervous System disorders. I am pleased to report on the progress that we made towards building a...
就在不到两年前，NLS制药公司寻求您的投资和支持，以推进我们治疗罕见睡眠障碍和其他罕见...
登录免费看全文
登录/注册